4.6 Article

OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity

Related references

Note: Only part of the references are listed.
Review Immunology

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

Michael Croft

ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)

Article Pharmacology & Pharmacy

Therapy Directed Against Thymic Stromal Lymphopoietin

Matthew J. Edwards

DRUG NEWS & PERSPECTIVES (2008)

Article Medicine, Research & Experimental

In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation

Dhaya Seshasayee et al.

JOURNAL OF CLINICAL INVESTIGATION (2007)

Article Dermatology

Efalizumab for severe atopic dermatitis: A pilot study in adults

Rodd Takiguchi et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)

Article Medicine, Research & Experimental

Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion

Marie Fischer et al.

JOURNAL OF CLINICAL INVESTIGATION (2006)

Review Allergy

The role of CD30 in atopic disease

Å Bengtsson

ALLERGY (2001)

Article Dermatology

Cytokine expression of skin T-lymphocytes from patients with atopic dermatitis

N Higashi et al.

ACTA DERMATO-VENEREOLOGICA (2001)